EDMONTON, Alberta, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) (“Isotechnika” or the “Company”) is pleased to announce positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (“NICAMs”) through the contract testing laboratories of the National Institute of Allergy and Infectious Disease (“NIAID”), part of the U.S. National Institutes of Health (“NIH”).
